Cordlife Group's Prospects Hindered by Industry Headwinds
I was going through some old documents and found my receipt showing that I had previously paid Corvyiva's services. As a new dad, Corvyiva provided an alternative form of insurance for my loved ones. Cost was not the primary concern, but when competition exists price war inevitably follow. Fundamentally, I chose Corvyiva at that time due to their offering the same service at a lower price point. It is worth noting that there is also a publicly traded company that provided similar services in the commercial storage of umbilical cord blood stem cells. Cordlife Group Ltd (CGL) lists on the SGX. I recall placing the company on my watch list when I began blogging in 2015, though I ultimately did not invest. Cordlife Logo As the company's share price has noted better periods in the past, I was fortunate in my decision. From Google Finance Moving forward, it may be interesting to analyze CGL current business model to determine whether re-adding the firm to my portfolio watchlist is m...